MMR vaccine given to 14 month old children, administered subcutaneously versus intramuscularly.
Completed
- Conditions
- Infectious Diseases, Measles, Mumps, Rubella.
- Registration Number
- NL-OMON20165
- Lead Sponsor
- ational Institute for Public Health and the Environment (RIVM)
- Brief Summary
AB Lafeber et al. RIVM report 000002 001, sep. 2001
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 67
Inclusion Criteria
1. Children aged 12 to 18 months in good general health.
Exclusion Criteria
1. Proven allergy for any of the vaccine components;
2. Contraindication for MMR vaccination (e.g. administration of blood products within 3 months before MMR vaccination);
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The occurrence of adverse events after the MMR vaccine administered subcutaneously versus intramuscularly as recorded by the parents (non-blinded).
- Secondary Outcome Measures
Name Time Method The immunogenicity of the MMR vaccine administered subcutaneously versus intramuscularly as measured by the antibody titers before and 12 weeks after vaccination. Antibody titers are determined by a twofold serial dilution ELISA.